20.06.2024 14:00:05 - dpa-AFX: GNW-Adhoc: Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
Paris, June 20, 2024. Sanofi and Biovac, a Cape Town, South Africa-based
biopharmaceutical company, announce today their local manufacturing partnership
to produce inactivated polio vaccines (IPV) in Africa. This agreement is
designed to enable regional manufacturing of polio vaccines to serve the
potential needs of over 40 African countries. This partnership with Sanofi makes
Biovac the first African producer of IPV on and for the African continent and
supports the Africa Centers for Disease Control and Prevention's ambition to
have 60 percent of local vaccines produced in Africa by 2040.
Thomas Triomphe
Executive Vice President, Vaccines, Sanofi
"For 40 years, Sanofi has supplied billions of polio vaccine doses globally,
supporting the world getting close to polio eradication. But with the COVID-19
pandemic, many routine pediatric vaccination programs were halted or disrupted.
Catching up will be key to preventing a rise in cases in many countries
worldwide and this Sanofi partnership with Biovac is a step in that direction.
Establishing this manufacturing partnership now, ahead of time, is key to
enabling Biovac's manufacturing capabilities for future international tenders."
Dr Morena Makhoana
Chief Executive Officer, Biovac
"We are very proud of this partnership with Sanofi, which will empower Biovac as
an African manufacturer to champion polio eradication on and for the continent
by bringing manufacturing of IPV doses closer to people needs."
Sanofi has been a critical partner of the Global Polio Eradication Initiative
since 1988 and has supplied the world and UNICEF with more than 1.5 billion
doses of IPV through GAVI, the Vaccine Alliance, which aims to vaccinate the
populations of more than 70 of the poorest countries on the planet with the aim
to eradicate polio.
Sanofi will continue to produce the bulk of IPV and Biovac, who will hold the
marketing authorization, will be responsible for late-stage formulation,
filling, packaging, and delivery of millions of IPV doses to UNICEF for GAVI
countries in Africa.
Biovac is a leading biotechnology company and a Centre of Excellence, rooted in
Africa, specializing in the development and manufacture of vaccines and other
biologicals for Africa and beyond. In collaboration with the South African
government, Biovac was established in 2003 to revive local human vaccine
development and manufacturing capability in Southern Africa.
Polio is a highly contagious disease which mainly affects children under five
years of age, who suffer the highest burden of temporary or permanent paralysis
and death. Polio is an incurable infection that can only be prevented through
immunization. Infected individuals shed the polio virus in the environment
through fecal matter, or through the droplets from a sneeze or cough of an
infected person, for several weeks. Almost 90 percent of infected people have no
symptoms or very mild symptoms that usually remain undetected. In others,
initial symptoms include fever, fatigue, headache, vomiting, aching muscles,
stiffness in the neck and pain in the limbs. One in 200 infections leads to
irreversible paralysis.
Over the last 30 years, under the Global Polio Eradication Initiative (GPEI),
2.5 billion children have been immunized against polio resulting in a 99 percent
reduction in the number of cases worldwide. At the end of 2023, polio was
endemic in only two countries (Afghanistan and Pakistan). As a result of the
global effort to eradicate the disease, almost 20 million people have been saved
from paralysis.
About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase
the miracles of science to improve people's lives. Our team, across the world,
is dedicated to transforming the practice of medicine by working to turn the
impossible into the possible. We provide potentially life-changing treatment
options and life-saving vaccine protection to millions of people globally, while
putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
(mailto:sandrine.guendoul@sanofi.com)
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
(mailto:evan.berland@sanofi.com)
Nicolas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.com
(mailto:nicolas.obrist@sanofi.com)
Victor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com
(mailto:victor.rouault@sanofi.com)
Timothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com
(mailto:%C2%A0timothy.gilbert@sanofi.com)
Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com
(mailto:thomas.larsen@sanofi.com)
Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com
(mailto:alize.kaisserian@sanofi.com)
Arnaud Delépine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.com
(mailto:arnaud.delepine@sanofi.com)
Felix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com
(mailto:felix.lauscher@sanofi.com)
Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.com
(mailto:keita.browne@sanofi.com)
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com
(mailto:nathalie.pham@sanofi.com)
Tarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.com
(mailto:Tarik.Elgoutni@sanofi.com)
Thibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
(mailto:thibaud.chatelet@sanofi.com)
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. These statements include
projections and estimates and their underlying assumptions, statements regarding
plans, objectives, intentions, and expectations with respect to future financial
results, events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements are
generally identified by the words "expects", "anticipates", "believes",
"intends", "estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties, many
of which are difficult to predict and generally beyond the control of Sanofi,
that could cause actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other things, the
uncertainties inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as well
as their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the fact that
product candidates if approved may not be commercially successful, the future
approval and commercial success of therapeutic alternatives, Sanofi's ability to
benefit from external growth opportunities, to complete related transactions
and/or obtain regulatory clearances, risks associated with intellectual property
and any related pending or future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and subsequent
changes thereto, and the impact that pandemics or other global crises may have
on us, our customers, suppliers, vendors, and other business partners, and the
financial condition of any one of them, as well as on our employees and on the
global economy as a whole. The risks and uncertainties also include the
uncertainties discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary
Statement Regarding Forward-Looking Statements" in Sanofi's annual report on
Form 20-F for the year ended December 31, 2023. Other than as required by
applicable law, Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.
Â